

MILDRED SCHEEL LECTURESHIP

9th Lecture

Prof. Dr. Margaret A. Shipp

Targetable Genetic Signatures in Lymphoid Malignancies

Chair: Prof. Dr. T. Wölfel | Prof. Dr. G. Heß

September 6th 2018

4:30 – 5:45 pm

Universitätsmedizin

Johannes Gutenberg-Universität Mainz

Geb. 102, großer Hörsaal

Langenbeckstraße 1

55131 Mainz

It is our pleasure to invite you to the 9th Mildred Scheel Lectureship given by Prof. Dr. Margaret Shipp, Harvard Medical School and Dana-Farber Cancer Institute, Boston, MA, USA. Within our 1st UCT Science Day and with support of „Frei für Forschung- neue Wege in der Medizin e.V.“ it is the first time that we coordinate the series and host the Mildred Scheel Lectureship in Mainz. With the unique Mildred Scheel Lectureship series we pay tribute to the outstanding commitment of Dr. Mildred Scheel in the fight against cancer, for which she is to this date nationally and internationally highly regarded.

Initiated in Heidelberg in a joint endeavor of the German Cancer Research Center and the German Cancer Aid, the Mildred Scheel Lectureship is for the sixth time spread to further Comprehensive Cancer Centers due to its great success. Our goals are to honor outstanding cancer researchers, and Medical and Clinician Scientists dedicated to the advancement of cancer research. In addition, through discussions with these pioneers, we would like to encourage in particular young scientists and MDs to pursue a scientific career.

We are looking forward to welcome you in Mainz in September!

Welcoming Remarks: Dr. Matthias Serwe, DKH
Reception at 6 pm



PD Dr.
Thomas Kindler
Geschäftsführender
Leiter UCT Mainz



Prof. Dr.
Matthias Theobald
Leiter UCT Mainz



Prof. Dr.
Ellen Closs
Vorsitzende:
„Frei für Forschung“



Margaret A. Shipp, MD

is Chief of the Division of Hematologic Neoplasia at Dana-Farber Cancer Institute, Director of the Lymphoma and Myeloma Program of the Dana-Farber/Harvard Cancer Center, and a Professor of Medicine at Harvard Medical School. Her clinical and laboratory research focuses on the clinical and molecular heterogeneity of the

large B-cell lymphomas (LBCLs) and Hodgkin lymphomas and the identification of unique lymphoma subtypes amenable to more targeted therapy. Dr. Shipp coordinated the development of the International Prognostic Index which is used worldwide to individualize treatment approaches to LBCLs and many other lymphoid malignancies. More recently, she has led efforts to develop molecular signatures of LBCLs and Hodgkin lymphomas, identify biologically distinct subsets of these diseases, and credential associated rational treatment targets including modulators of the host anti-tumor immune response. These studies are already leading to more specific and more effective treatment approaches in these diseases.

Dr. Shipp received her Doctor of Medicine from Washington University School of Medicine and completed an internal medicine internship and residency at Barnes Hospital, Washington University.



Mildred Scheel

* 31. December 1932 · † 13. May 1985

Dr. Mildred Scheel, a German physician and wife of the 4th German Federal President founded the German Cancer Aid in 1974. Her vision was to fight cancer at all levels and improve the treatment and well-being of patients.

At the same time she managed a family life with three children. For her personal commitment she received innumerable honours and gained an outstanding international reputation. With her life philosophy "if one really wants something, one can do it..." she has served as a role model for many women all over the world.